Express Scripts executive requests Gilead lower price of Sovaldi, Harvoni
March 13, 2017
A recent interview with a Gilead Sciences executive pointing fingers for drug costs at pharmacy benefit managers spurred a formal letter from Express Scripts requesting a lower price for the company’s popular hepatitis C medications.
In an interview with Bloomberg, Gilead’s executive vice president, Jim Meyers, stated that pharmacy benefit managers would refuse to cover company products if prices were significantly lowered. “If we just lowered the cost of Sovaldi from $85,000 to $50,000, every payer would rip up our contract,” Meyers said to Bloomberg.
March 13, 2017
A recent interview with a Gilead Sciences executive pointing fingers for drug costs at pharmacy benefit managers spurred a formal letter from Express Scripts requesting a lower price for the company’s popular hepatitis C medications.
In an interview with Bloomberg, Gilead’s executive vice president, Jim Meyers, stated that pharmacy benefit managers would refuse to cover company products if prices were significantly lowered. “If we just lowered the cost of Sovaldi from $85,000 to $50,000, every payer would rip up our contract,” Meyers said to Bloomberg.
Continue reading @ Healio
Of Interest
The controversy over expensive new drugs for hepatitis C
Link to research and news articles addressing the high cost of hepatitis C drugs; insurance restrictions - private insurers/Medicaid - and availability of generic versions/India, Egypt and other lower-income countries or through online "buyers clubs"
The controversy over expensive new drugs for hepatitis C
Link to research and news articles addressing the high cost of hepatitis C drugs; insurance restrictions - private insurers/Medicaid - and availability of generic versions/India, Egypt and other lower-income countries or through online "buyers clubs"
No comments:
Post a Comment